Thromboplastin components

Antihemophilic factor B, Christmas factor, plasma thromboplastin component (PTC)... 

Pharmacology Vitamin K promotes the hepatic synthesis of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The mechanism by which vitamin K promotes formation of these clotting factors involves the hepatic post-translational carboxylation of specific glutamate residues to gamma-carboxylglutamate residues in proteins involved in coagulation, thus leading to their activation. 

PlaqueniP hydroxychloroquine, plasma thromboplastin component factor IX. plasminogen activator inhibitor (proteinase inhibitor PAI) is a peptide containing 376-379 amino acid residues, found in 3 forms. It is an ENZYME INHIBITOR actively involved in the control of haemostatic blood clotting factors. Increased levels are found in metastases it is a possible diagnostic agent and target for anticancer chemotherapy, plasmin fibrinolysin. 

A2. Adelson, E., Rheingold, J. J., Parker, 0., Steiner, M., and Kirby, J. C., The survival of factor VIII (antihemophilic globulin) and factor IX (plasma thromboplastin component) in normal humans. J. Clin. Invest. 42, 1040-1047 (1963). 

The conformational change in antithrombin III induced by heparin allows the molecule to bind to, and inactivate, factors involved in the clotting cascade. Primary factors affected are the activated forms of factor IX ( Christmas factor, or plasma thromboplastin component) and X ( Stuart-Prower factor ). 

The coumarin anticoagulants are employed in therapy to depress blood coagulation and to prevent thrombosis in diseases of the coronary artery and in other conditions [419]. These compounds act only in vivo by blocking the synthesis of four proteins in the prothrombin complex (factors II = prothrombin, VII = proconvertin, IX = plasma thromboplastin component, and X = Stuart-Prower factor) necessary for the normal blood coagulation process. These proteins are... 

The antihemophilic globulin, the factor absent from the blood in the best-known hemophilia, combines stoichiometrically with a platelet thromboplastic factor, and the two compounds act like precursors, yielding a product itself a precursor. For thromboplastin, the product is prothromboplastin. The platelet thromboplastin component acts like a catalyst consequently, its concentration does not change during the reaction. The prothromboplastin combines with another compound called the plasma-accelerating globulin to yield a new product, namely, thromboplastin. 

Intrinsic thromboplastin is formed in three steps. The first step involves the plasma thromboplastin component the antihemophilic globulin, the thromboplastin antecedent (PTA), the Hageman factor, and the Stuart-Prower factor. All these factors interact rapidly they have not been purified, and therefore nothing is known of their molecular structure. With so little information, it would be rather naive to anticipate that the exact mode of interaction of these different factors would be known. 

In the second step of intrinsic thromboplastin formation, active PTA reacts with inactive plasma thromboplastin component (PTC) to convert it to active PTC. The active PTC reacts with AHG and factor X to yield a compound referred to here as product I. What is substrate and what is enzyme in this reaction are not known. A little is known of product I because it has been possible to purify it chromatographically on DEAE and on continuous flow electrophoresis. Its properties will be discussed below. 

---